{"id":"W2597108928","doi":"10.1182/blood.v116.21.985.985","title":"Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Lenalidomide; Thalidomide; Multiple myeloma; Bortezomib; Refractory (planetary science); Internal medicine; Clinical endpoint; Regimen; Phases of clinical research; Progression-free survival; Gastroenterology; Surgery; Oncology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002684771,0.001715401,0.001706406,0.0004287993,0.0005005085,0.0007966905,0.0008004415,0.001405214,0.003184112],"category_scores_gemma":[0.001073013,0.0006295183,0.001083935,0.0002913467,0.0007882678,0.0009524649,0.0003771839,0.003571091,0.0008665295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007883924,"about_ca_system_score_gemma":0.001446769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009901564,"about_ca_topic_score_gemma":0.002226901,"domain_scores_codex":[0.9993429,0.0003446701,0.00003313016,0.00009419595,0.00005037971,0.0001348039],"domain_scores_gemma":[0.9986957,0.0002657462,0.0002107677,0.0000811302,0.00007822152,0.0006685542],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7377933,0.1066509,0.0107427,0.0006578356,0.001200946,0.0003721302,0.0004108684,0.002802602,0.05502042,0.0002474877,0.008128142,0.07597262],"study_design_scores_gemma":[0.3920324,0.5719855,0.02647686,0.00002708565,0.0006074995,0.0002861255,0.00005157689,0.001033447,0.004399069,0.0001603532,0.002906755,0.00003336711],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902649,0.001367369,0.0004044565,0.0004549799,0.0001006443,0.002376643,0.002194148,0.00009984522,0.002736926],"genre_scores_gemma":[0.9858469,0.0009649858,0.001329744,0.0009292364,0.0002284598,0.002191807,0.00534501,0.00004663575,0.00311721],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003184112,"threshold_uncertainty_score":0.0141986,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04297886026335334,"score_gpt":0.3249800669720499,"score_spread":0.2820012067086966,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}